Morpholine → (S)-2-fluoro-7-(2-fluoropyridin-3-yl)-3-morpholino-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine

Participants

Reaction Steps

A vial charged with (S)-2-fluoro-7-(2-fluoropyridin-3-yl)-3-iodo-5′H-spiro[chromeno[2,3-b]pyridine-5,4′-oxazol]-2′-amine (0.20 g, 0.41 mmol, prepared as described in Method BB34) and Ruphos palladacycle (0.032 g, 0.041 mmol) was treated with morpholine (0.18 mL, 2.03 mmol) and 4 mL THF. LiHMDS (2.03 mL, 2.03 mmol) was added, the vial was capped under argon, and the reaction mixture was allowed to stir overnight. The reaction mixture was purified directly by column chromatography [0-80% (9:1 DCM/MeOH)/heptane] yielding (S)-2-fluoro-7-(2-fluoropyridin-3-yl)-3-morpholino-5′H-spiro[chromeno[2,3-b]pyridine-5,4′-oxazol]-2′-amine (0.044 g, 0.097 mmol). [M+H]+=452.0

Provenance & Evidence